Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Alector, Inc.

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports First Quarter 2025 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
Alector Provides Executive Leadership Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Host Mid-Year Earnings Conference Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
From Alector, Inc.
Via GlobeNewswire
Tickers ABBV ALEC
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Participate in Upcoming Healthcare Conferences
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
From Alector, Inc.
Via GlobeNewswire
Tickers ALEC GSK
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.